Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of plasmodium falciparum malaria in a human challenge model

Clinical Infectious Diseases

Volumn 54, Issue 2, 2012, Pages 232-239

  Deye, Gregory A ^a   Miller, R Scott ^a   Miller, Lori ^a   Salas, Carola J ^b   Tosh, Donna ^a   MacAreo, Louis ^a   Smith, Bryan L ^a   Fracisco, Susan ^a   Clemens, Emily G ^c   Murphy, Jittawadee ^a   Sousa, Jason C ^a   Dumler, J Stephen ^c   Magill, Alan J ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Peru   (Peru)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; PLACEBO; PROGUANIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSCOPY; MODEL; MOSQUITO; NAUSEA; NORMAL HUMAN; PARASITEMIA; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTECTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SPOROZOITE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOLUNTEER;

ADULT; ANTIMALARIALS; AREA UNDER CURVE; ATOVAQUONE; CHEMOPREVENTION; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLACEBOS; PLASMODIUM FALCIPARUM; PROGUANIL; SPOROZOITES;

EID: 84555209239     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir770     Document Type: Article

References (24)

1. Leder K, Black J, O'Brien D, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004; 39:1104-12. (Pubitemid 40169306)
2. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119-30. (Pubitemid 43076709)
3. Arguin P, Steele S. Malaria. In: Brunette G, ed. Health information for international travel. Atlanta, GA: US Department of Health and Human Services, Public Health Service, 2010.
4. Mali S, Steele S, Slutsker L, Arguin PM. Malaria surveillance-United States, 2008. MMWR Surveill Summ 2010; 59:1-15.
5. Malarone [package insert]. Middlesex, United Kingdom: GlaxoSmith-Kline; 2009.
6. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997; 61:518-30. (Pubitemid 27261756)
7. Edstein MD, Kotecka BM, Anderson KL, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother 2005; 49: 4421-2. (Pubitemid 41401005)
8. Edstein MD, Veenendaal JR, Scott HV, Rieckmann KH. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. Chemotherapy 1988; 34:385-92.
9. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-13. (Pubitemid 28105340)
10. Shanks GD, Ragama BO, Oloo AJ. Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya. Trans R Soc Trop Med Hyg 1999; 93:304-5. (Pubitemid 29348828)
11. Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825-33.
12. Polhemus ME, Remich S, Ogutu B, et al. Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria. Antimicrob Agents Chemother 2008; 52:1493-5. (Pubitemid 351522016)
13. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60:831-6. (Pubitemid 29233089)
14. Fairley N. Reseraches on paludrine (M.4888) in malaria: an experimental investigation undertaken by L.H.Q. Medical research Unit, Cairns Australia. Trans Roy Soc Trop Med Hyg 1946; 40:101-51.
15. Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986; 35:66-8. (Pubitemid 16140838)
16. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I follow-up study cohort. Lancet 2008; 371:923-31. (Pubitemid 351375276)
17. Epstein JE, Rao S, Williams F, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparuminfected mosquitoes: an update. J Infect Dis 2007; 196:145-54. (Pubitemid 46982749)
18. Gay F, Bustos D, Traore B, et al. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 1997; 56:315-17. (Pubitemid 27181019)
19. Ohrt C, Purnomo , Sutamihardja MA, Tang D, Kain KC. Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J Infect Dis 2002; 186:540-6. (Pubitemid 34876264)
20. Rolan PE, Mercer AJ, Weatherley BC, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 1994; 37:13-20. (Pubitemid 24204575)
21. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44:2100-8. (Pubitemid 30484433)
22. Schwobel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003; 2:5.
23. Anderson SL, Berman J, Kuschner R, et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995; 123:771-3.
24. Taylor WR, Richie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999; 28:74-81. (Pubitemid 29246129)